Home > Expanded Access > Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Boehringer Ingelheim

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatmen...

Official Title: 
An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options
Brief Summary: 
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
Approved for marketing
HIV Infections

Drug: Tipranavir
Tipranavir 250 mg soft elastic capsules

Eligibility Criteria: 

Inclusion criteria:

Patients aho have a positive serology HIV antibody test confirmed by Western blot, p24
antigen assay, HIV-1 RNA or HIV culture and are highly pre-treated and virus resistant to
multiple protease inhibitors.

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 2 Years
Countries: 
Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom, United States
Locations: 

1182.58.31
Scottsdale, Arizona,

1182.58.29
Los Angeles, California,

1182.58.34 Campus Code 696446
Los Angeles, California,

1182.58.42 Synergy Hematology/Oncology
Los Angeles, California,

1182.58.43
Los Angeles, California,

1182.58.03
San Francisco, California,

1182.58.33 Kaiser Permanente Medical Center, Clinical Trials Unit
San Francisco, California,

1182.58.37 AIDS Health Care Foundation
Los Angeles, Connecticut,

1182.58.41 Circle Medical, LLC
Norwalk, Connecticut,

1182.58.28
Washington, District of Columbia,

1182.58.38
Miami Beach, Florida,

1182.58.40 Drs. Raben and Feldman Research Associates
South Miami, Florida,

1182.58.23 Hillsborough County Health Department
Tampa, Florida,

1182.58.36 Suite 525
Atlanta, Georgia,

1182.58.08
Honolulu, Hawaii,

1182.58.22
Chicago, Illinois,

1182.58.32
New Orleans, Louisiana,

1182.58.15
Boston, Massachusetts,

1182.58.19 Henry Ford Hospital
Detroit, Michigan,

1182.58.04 Kansas City Free Health Clinic
Kansas City, Missouri,

1182.58.25 Wohl Clinic
St. Louis, Missouri,

1182.58.02 Wellness Center
Las Vegas, Nevada,

1182.58.09 Polari Medical Group
New York, New York,

1182.58.30
Chapel Hill, North Carolina,

1182.58.06 University of Cincinnati Medical Center, Infectious diseases
Cincinnati, Ohio,

1182.58.35
Portland, Oregon,

1182.58.14
Philadelphia, Pennsylvania,

1182.58.20 University of Pittsburgh
Pittsburgh, Pennsylvania,

1182.58.01 Boehringer Ingelheim Investigational Site
Columbia, South Carolina,

1182.58.10 Comprehensive Care Center
Nashville, Tennessee,

1182.58.18 University of Texas Southwest Medical Center at Dallas
Dallas, Texas,

1182.58.07
Houston, Texas,

1182.58.039 Olmos Park Medical Associates
San Antonio, Texas,

1182.58.11 Swedish Medical Center
Seattle, Washington,

1182.58.44 VW Hospital and Clinics
Madison, Wisconsin,

Boehringer Ingelheim
Study Chair
Boehringer Ingelheim

Boehringer Ingelheim
EA Number: 
MeSH Terms: 
Infection, Communicable Diseases, HIV Infections, Acquired Immunodeficiency Syndrome, Tipranavir
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.